Core Viewpoint - Inpai Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, with Goldman Sachs and CICC as joint sponsors [1] Group 1: Company Overview - Inpai Pharmaceuticals is a commercial-stage biotechnology company focused on precision cancer therapies based on synthetic lethality mechanisms [1] - The company's core product, Senaparib (PARP1/2 inhibitor), was approved in China for first-line maintenance treatment of ovarian cancer in January 2025 and is now commercialized [1] - Senaparib has been accepted by the European Medicines Agency (EMA) and is expected to receive approval in the second half of 2026, with plans to participate in negotiations for inclusion in China's National Medical Insurance Drug List in Q4 2025 [1] Group 2: Product Pipeline - Inpai Pharmaceuticals has multiple clinical-stage assets, including IMP1734 (selective PARP1 inhibitor), IMP9064 (selective ATR inhibitor), and IMP1707 (selective PARP1 inhibitor) [1] - The company's pipeline also includes preclinical candidates targeting WEE1, PKMYT1/WEE1, DHX9, ATM, USP1, and CHK1/2 [1] Group 3: Fundraising Purpose - The funds raised will be used for the development and commercialization of the core product Senaparib, clinical development of key products IMP1734 and IMP9064, and research and development of other pipeline assets [1]
英派药业递表港交所 高盛、中金为联席保荐人
Zheng Quan Shi Bao Wang·2025-09-29 00:45